ArticleNoro psikiyatri arsivi2026
Pembrolizumab Experience in a Patient with Progressive Multifocal Leukoencephalopathy Following Multiple Myeloma Treatment: A Case Report and Literature Review.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Progressive multifocal leukoencephalopathy (PML) is a progressive demyelinating infection of the central nervous system. PML arises in immunosuppressive conditions or circumstances necessitating immunosuppressive treatment, such as malignancies. Recently, data have been published regarding the use of different immune checkpoint inhibitors (ICIs) for the treatment of PML. However, the extent to which ICIs impact and improve PML in individual patients remains uncertain. Case: A 68-year-old female patient, diagnosed with multiple myeloma in 2012 and with a history of using various chemotherapeutic agents, presented with dizziness, gait disturbances, and speech difficulties. The patient was diagnosed with PML and started on pembrolizumab treatment. This treatment led to improvements in both clinical symptoms and imaging findings. Conclusion: Regardless of the underlying cause in PML, the use of ICIs can improve the clinical course of the disease and prolong the patient's lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.